Law360: O’Melveny Steers Cancer-Focused Biotech Firm’s US$58M IPO
September 29, 2023
O’Melveny represented Adlai Nortye Ltd. in its IPO on the Nasdaq. Adlai Nortye expects to receive aggregate gross proceeds of US$97.5 million, including US$57.5 million from public offering and US$40 million from the concurrent private placement. The O’Melveny team was led by partners Ke Geng, Ke Zhu, and Vincent Lin, counsel Aaron Xin, Bo Li, and Dawn Lim, associate Fan Wu, and legal consultants Minhui Chen, Xingyan Zhou, and Daniel Tian.
Read the full article here.